{"body":"NICE","country":"United Kingdom","type":"HTA","currency":"GBP","indication":"NSCLC","submission_date":"2026-09-01","days_remaining":93,"pico_questions":[{"id":"NICE-PICO-01","population":"Adults with metastatic NSCLC, PD-L1 TPS≥50%, no prior systemic therapy","intervention":"Test drug, monotherapy, q3w until progression","comparators":["pembrolizumab monotherapy","platinum doublet chemotherapy","atezolizumab"],"outcomes":["overall survival","PFS","ORR","DoR","AEs ≥G3","HRQoL (EORTC QLQ-C30)"],"source":"nice_scope"},{"id":"NICE-PICO-02","population":"Adults with metastatic NSCLC, PD-L1 TPS≥50%, no prior systemic therapy","intervention":"Test drug, monotherapy, q3w until progression","comparators":["atezolizumab","platinum doublet chemotherapy"],"outcomes":["overall survival","PFS","ORR","DoR","AEs ≥G3","HRQoL (EORTC QLQ-C30)"],"source":"nice_scope"},{"id":"NICE-PICO-03","population":"Adults with metastatic NSCLC, PD-L1 TPS≥50%, no prior systemic therapy","intervention":"Test drug, monotherapy, q3w until progression","comparators":["platinum doublet chemotherapy","atezolizumab","pembrolizumab monotherapy"],"outcomes":["overall survival","PFS","ORR","DoR","AEs ≥G3","HRQoL (EORTC QLQ-C30)"],"source":"nice_scope"}],"modules":[{"code":"NICE_A","name":"Module A — Decision problem & technology","required":true,"completion":0.92},{"code":"NICE_B","name":"Module B — Clinical effectiveness (SLR + RCTs)","required":true,"completion":0.67},{"code":"NICE_C","name":"Module C — Cost effectiveness model (CEM, ICER, £/QALY)","required":true,"completion":0.66},{"code":"NICE_D","name":"Module D — Budget impact analysis (BIA)","required":true,"completion":0.68},{"code":"NICE_PAS","name":"Patient Access Scheme (PAS)","required":false,"completion":0.9},{"code":"NICE_EAG","name":"External Assessment Group report","required":true,"completion":0.46}],"requirements":[{"requirement_id":"NICE-001","category":"Decision problem","description":"Final scope aligned with NICE STA matrix","evidence_type":"SLR","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P0","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-002","category":"Clinical evidence","description":"RCT data versus NICE-agreed comparator","evidence_type":"RCT","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P0","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-003","category":"Clinical evidence","description":"Indirect treatment comparison vs current standard of care","evidence_type":"ITC_NMA","status":"missing","evidence_available":false,"gap_severity":"major","estimated_months_to_close":2,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-004","category":"Clinical evidence","description":"Systematic literature review per PMG24 methods","evidence_type":"SLR","status":"in_progress","evidence_available":false,"gap_severity":"blocker","estimated_months_to_close":4,"priority":"P0","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-005","category":"Clinical evidence","description":"Pivotal Phase 3 published results (peer-reviewed)","evidence_type":"RCT","status":"missing","evidence_available":false,"gap_severity":"blocker","estimated_months_to_close":10,"priority":"P0","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-006","category":"Cost-effectiveness","description":"Partitioned-survival cost-effectiveness model (CEM)","evidence_type":"ECON_MODEL","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P0","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-007","category":"Cost-effectiveness","description":"ICER deterministic + PSA at £20k-£50k/QALY thresholds","evidence_type":"ECON_MODEL","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P0","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-008","category":"Cost-effectiveness","description":"Model validation (face, internal, cross, external)","evidence_type":"ECON_MODEL","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-009","category":"Cost-effectiveness","description":"Discounting at 3.5% per Treasury Green Book","evidence_type":"ECON_MODEL","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-010","category":"Cost-effectiveness","description":"Severity modifier (1.0 / 1.2 / 1.7) justification","evidence_type":"ECON_MODEL","status":"in_progress","evidence_available":false,"gap_severity":"major","estimated_months_to_close":4,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-011","category":"Cost-effectiveness","description":"End-of-life criteria evidence (if applicable)","evidence_type":"ECON_MODEL","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-012","category":"Cost-effectiveness","description":"Equity weighting analysis (if QALY shortfall claimed)","evidence_type":"ECON_MODEL","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-013","category":"Patient-reported outcomes","description":"EQ-5D-5L utility data from pivotal trial","evidence_type":"PRO","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-014","category":"Patient-reported outcomes","description":"Mapped utilities from disease-specific instruments","evidence_type":"PRO","status":"in_progress","evidence_available":false,"gap_severity":"minor","estimated_months_to_close":4,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-015","category":"Long-term extrapolation","description":"Survival extrapolation beyond trial follow-up","evidence_type":"ECON_MODEL","status":"in_progress","evidence_available":false,"gap_severity":"major","estimated_months_to_close":4,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-016","category":"Long-term extrapolation","description":"Parametric model fit (Weibull/log-normal/gen. gamma) justification","evidence_type":"ECON_MODEL","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-017","category":"Long-term extrapolation","description":"Cure modelling assumptions if claimed","evidence_type":"ECON_MODEL","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-018","category":"Budget impact","description":"5-year BIA for NHS England","evidence_type":"BIA","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-019","category":"Budget impact","description":"Eligible patient flow diagram + treatment pathway","evidence_type":"BIA","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-020","category":"Patient input","description":"Patient organisation submission","evidence_type":"PATIENT_INPUT","status":"in_progress","evidence_available":false,"gap_severity":"minor","estimated_months_to_close":3,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-021","category":"Patient input","description":"Lay summary of patient experience for committee","evidence_type":"PATIENT_INPUT","status":"missing","evidence_available":false,"gap_severity":"minor","estimated_months_to_close":1,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-022","category":"Clinical expert input","description":"EAG-nominated clinical lead statement","evidence_type":"CLINICAL_EXPERT","status":"missing","evidence_available":false,"gap_severity":"minor","estimated_months_to_close":1,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-023","category":"Clinical expert input","description":"Specialist society endorsement (e.g. UKONS, BSH)","evidence_type":"CLINICAL_EXPERT","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-024","category":"Real-world evidence","description":"Registry data on current treatment pathway","evidence_type":"RWE","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-025","category":"Real-world evidence","description":"RWE on subsequent therapies (post-progression)","evidence_type":"RWE","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-026","category":"Subgroup analysis","description":"Pre-specified subgroups for severity modifier","evidence_type":"RCT","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-027","category":"Subgroup analysis","description":"Biomarker-defined subgroup outcomes","evidence_type":"RCT","status":"in_progress","evidence_available":false,"gap_severity":"major","estimated_months_to_close":10,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-028","category":"Safety","description":"Long-term safety follow-up commitment","evidence_type":"RCT","status":"in_progress","evidence_available":false,"gap_severity":"minor","estimated_months_to_close":8,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-029","category":"Safety","description":"AE rates with CTCAE grading by treatment arm","evidence_type":"RCT","status":"available","evidence_available":true,"gap_severity":"none","estimated_months_to_close":null,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-030","category":"Resource use","description":"Healthcare resource use estimates from trial / RWE","evidence_type":"RWE","status":"in_progress","evidence_available":false,"gap_severity":"minor","estimated_months_to_close":12,"priority":"P2","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-031","category":"PAS","description":"Confidential commercial access scheme (PAS) proposal","evidence_type":"BIA","status":"in_progress","evidence_available":false,"gap_severity":"major","estimated_months_to_close":1,"priority":"P1","pico_refs":["NICE-PICO-01"]},{"requirement_id":"NICE-032","category":"Equality","description":"Equality impact assessment / EHRC compliance","evidence_type":"PATIENT_INPUT","status":"in_progress","evidence_available":false,"gap_severity":"none","estimated_months_to_close":1,"priority":"P3","pico_refs":["NICE-PICO-01"]}],"summary":{"total_requirements":32,"met":18,"gap":14,"blocker_gaps":2},"decision_status":"pending"}